China National Medicines Co., Ltd. (600511) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

China National Medicines Co., Ltd.

Why is China National Medicines Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 4.83% and Operating profit at 1.81% over the last 5 years

Flat results in Sep 25

OPERATING CASH FLOW(Y) Lowest at CNY 688.41 MM
ROCE(HY) Lowest at 11.61%
DEBT-EQUITY RATIO (HY) Highest at -28.23 %

With ROE of 11.85%, it has a attractive valuation with a 1.24 Price to Book Value

Over the past year, while the stock has generated a return of -0.70%, its profits have fallen by -12%
At the current price, the company has a high dividend yield of 2.8

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 22.49% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -0.70% returns

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to China National Medicines Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is China National Medicines Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

China National Medicines Co., Ltd.

-5.17%

-0.90

14.35%

China Shanghai Composite

13.33%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.83%

EBIT Growth (5y)

1.81%

EBIT to Interest (avg)

60.23

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.31

Sales to Capital Employed (avg)

2.60

Tax Ratio

24.71%

Dividend Payout Ratio

30.18%

Pledged Shares

Institutional Holding

ROCE (avg)

22.18%

ROE (avg)

14.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.24

EV to EBIT

8.43

EV to EBITDA

7.49

EV to Capital Employed

1.33

EV to Sales

0.33

PEG Ratio

Dividend Yield

2.78%

ROCE (Latest)

15.83%

ROE (Latest)

11.85%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

INTEREST COVERAGE RATIO(Q)

Highest at 10,830.08

RAW MATERIAL COST(Y)

Fallen by -1.24% (YoY

NET SALES(Q)

Highest at CNY 13,747.35 MM

NET PROFIT(Q)

Highest at CNY 543.72 MM

EPS(Q)

Highest at CNY 0.72

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 688.41 MM

ROCE(HY)

Lowest at 11.61%

DEBT-EQUITY RATIO (HY)

Highest at -28.23 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 9.33 times

Here's what is working for China National Medicines Co., Ltd.

Interest Coverage Ratio

Highest at 10,830.08

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales

Highest at CNY 13,747.35 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Profit

Highest at CNY 543.72 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.72

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -1.24% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for China National Medicines Co., Ltd.

Operating Cash Flow

Lowest at CNY 688.41 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio

Highest at -28.23 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 9.33 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio